Vorinostat, also known as SAHA (suberoylanilide hydroxamic acid), is a histone deacetylase inhibitor (HDAC inhibitor) used in the treatment of cancer. It was the first HDAC inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma (CTCL).
